Verrica Pharmaceuticals INC Form 4 insider transactions

Lawrence Eichenfield, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares of common stock.

Verrica Pharmaceuticals Inc. director Diem Nguyen acquired 16,000 stock options with an exercise price of $6.04, vesting over 12 months starting July 5, 2026.

Verrica Pharmaceuticals Inc. director Mark A. Prygocki Sr. acquired 16,000 stock options with an exercise price of $6.04.

Gavin Corcoran, a Director at Verrica Pharmaceuticals Inc., acquired stock options for 16,000 shares.

Verrica Pharmaceuticals' Interim CFO, John J. Kirby, acquired 10,000 shares of common stock through a fully vested restricted stock unit award.

Verrica Pharmaceuticals' Chief Medical Officer, Noah L. Rosenberg, acquired 2,357 shares of common stock and 589 Series C warrants.

Verrica Pharmaceuticals' Interim CFO, John J. Kirby, acquired 3,536 shares of common stock and 884 Series C Warrants, increasing his beneficial ownership.

Verrica Pharmaceuticals' Chief Operating Officer, David Zawitz, purchased 10,000 shares of common stock and associated warrants, signaling confidence in the company's future.

Verrica Pharmaceuticals CEO Jayson Rieger acquired 94,311 shares of common stock and 23,577 Series C warrants, increasing his direct beneficial ownership.

Verrica Pharmaceuticals Director and 10% owner Paul B. Manning acquired over $17.5 million in common stock and Series C warrants.

Verrica Pharmaceuticals Inc. Director Gavin Corcoran was granted 20,000 stock options with an exercise price of $0.58, vesting over 12 months.

Verrica Pharmaceuticals Inc. Director Diem Nguyen acquired 20,000 stock options with an exercise price of $0.58, vesting over 12 months, as reported in a recent SEC Form 4 filing.

Lawrence Eichenfield, a Director at Verrica Pharmaceuticals Inc., acquired 20,000 stock options with an exercise price of $0.58, vesting over 12 months starting July 5, 2025.

Verrica Pharmaceuticals Inc. Director Mark A. Prygocki was granted 20,000 stock options with an exercise price of $0.58, vesting over 12 months beginning July 5, 2025.

Gavin Corcoran, a director at Verrica Pharmaceuticals, acquired stock options for 17,502 shares on March 31, 2025, according to a Form 4 filing.

Noah L. Rosenberg, Chief Medical Officer of Verrica Pharmaceuticals, reports the acquisition of stock options.

Verrica Pharmaceuticals CEO Jayson Rieger was granted 850,000 employee stock options on March 14, 2025, according to a Form 4 filing.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, reports the acquisition of stock options and the sale of common stock to cover tax obligations.

Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, amends a previous SEC filing to accurately reflect restricted stock unit awards following the first commercial sale of VP-102.

Verrica Pharmaceuticals' CFO, Terry Kohler, files an amended SEC Form 4 to correct the number of restricted stock units (RSUs) awarded, following the first commercial sale of VP-102.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals, amends a previous SEC Form 4 filing to accurately reflect the number of restricted stock units (RSUs) awarded following the first commercial sale of VP-102.

Verrica Pharmaceuticals CEO Ted White received 150,000 restricted stock units (RSUs) that vested upon the first commercial sale of VP-102, and an amendment was filed to correct a misreporting in the initial Form 4 regarding the total number of RSUs awarded.

Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, files an amendment to a previous SEC Form 4 to correct the number of restricted stock units (RSUs) awarded.

Verrica Pharmaceuticals' Chief Operating Officer, David Zawitz, was granted 950,000 stock options on December 9, 2024, which vest over time.

Verrica Pharmaceuticals CEO Jayson Rieger acquired shares and warrants through investment units and a gift, increasing his holdings in the company.

Director John A. Stalfort III of Verrica Pharmaceuticals acquired common stock and warrants through a private placement, increasing his holdings.

Paul B. Manning, a director at Verrica Pharmaceuticals, has acquired a substantial number of shares and warrants through investment units, increasing his beneficial ownership.

Interim CFO John J. Kirby of Verrica Pharmaceuticals acquired 54,267 restricted stock units (RSUs) on November 6, 2024, which will vest on May 4, 2025, subject to continued service.

Verrica Pharmaceuticals CEO and President, Jayson Rieger, acquired 2,000,000 employee stock options on November 6, 2024, at an exercise price of $0.7463.

Christopher G. Hayes, Chief Legal Officer of Verrica Pharmaceuticals Inc., acquired 50,000 employee stock options on October 9, 2024.